Table 2.
Treatment characteristics
| Total dose (Gy) | |
|---|---|
| Primary tumor | |
| Group 1 (PT-Ø* < 2.5 cm, n = 17) | 73.8 |
| Group 2 (2.5 – 4.5 cm, n = 52) | 79.2 |
| Group 3 (4.5 – 6.0 cm, n = 20) | 84.6 |
| Group 4 (> 6.0 cm, n = 8) | 90.0 |
| Nodes | 61.2 |
| Nodes electively** | 45 |
| Fractional dose (Gy) | 1.8 bid |
| Interval | 8 h |
| Radiation treatment duration (days, median, range) | 30 (28 – 37) |
| Chemotherapy before radiotherapy (patients, %) | 91 (91) |
| Cycles (n, median, range) | 2 (1 – 4) |
| Carboplatin | 76 (76) |
| Cisplatin | 15 (15) |
| Gemcitabine | 40 (40) |
| Pemetrexed | 36 (36) |
| Navelbine | 12 (12) |
| Etoposide | 2 ( 2) |
| Taxotere | 1 ( 1) |
| Durvalumab, consolidation post radiotherapy (patients, %) | |
| Started | 36 (36) |
| Completed at 12 months, without toxicity | 11 (11) |
| Incomplete, until now well tolerated | 12 (12) |
| Premature termination | 13 (13) |
| PD-L1-negativity | 4 (4) |
| Progression of disease | 4(4) |
| Toxicity | 2 (2) |
| Intercurrent death | 2 (2) |
| Patient request | 1 (1) |
*PT–Ø = Diameter of the primary tumor (mean of three perpendicular diameters);
**To a restricted nodal volume